I
Intensity Therapeutics D
D
INTS
4.60000
USD
0.34
(7.85%)
Market Closed
Volume
0
EPS
-4
Div Yield
-
P/E
-2
Market Cap
15,018,443
Title: Intensity Therapeutics Inc.
Sector: Healthcare
Industry: Biotechnology
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.